Background
Monocyte chemotactic protein-1 [MCP-1; chemokine C-C Ligand-2 (CCL-2)] is upregulated in ischemia-reperfusion injury and is a promising biomarker of inflammation in cardiac surgery.
Methods
We measured pre- and postoperative plasma MCP-1 levels in adult patients undergoing cardiac surgery to evaluate the association of perioperative MCP-1 levels with acute kidney injury (AKI) and mortality in TRIBE-AKI- a prospective, multicenter, observational cohort.
Results
Of the 972 participants in the study, 329 (34%) developed AKI and 45 (5%) developed severe AKI. During median follow-up of 2.9 (2.2–3.5) years, 119 (12%) participants died. MCP-1 levels were significantly higher in those who developed AKI and mortality as compared to those without AKI and mortality, respectively. Participants with preoperative MCP-1 level in the highest tertile (>196 pg/ml) had an increased AKI risk as compared to those in the lowest tertile [<147 pg/ml; OR, 1.43 (1.00–2.05)]; the association appeared similar but was not significant for the severe AKI outcome [OR, 1.48 (0.62–3.54)]. As compared with participants with preoperative MCP-1 level in the lowest tertile, those in the highest tertile had higher adjusted mortality risk [HR, 1.82 (1.40–2.38)]. Similarly, as compared to participants with postoperative MCP-1 level in the lowest tertile, those in the highest tertile had higher adjusted mortality risk [HR, 1.95 (1.09–3.49)].
Conclusions
Higher plasma MCP-1 is associated with increased AKI and mortality risk after cardiac surgery. MCP-1 could be used as a biomarker to identify high-risk patients for potential AKI prevention strategies in the setting of cardiac surgery.